文献速递神经肿瘤

混合认知行为疗法治疗稳定期弥漫性胶质瘤重度疲乏的贝叶斯自适应随机试验

Bayesian adaptive randomized trial of blended cognitive behavioral therapy for severe fatigue in stable diffuse glioma.
PubMed 文献 · Neuro Oncol · 2026-01-01

本研究为贝叶斯自适应随机对照试验,纳入47例稳定期弥漫性胶质瘤伴重度疲乏患者,随机接受12周混合认知行为疗法(bCBT)或等待名单对照(WLC)。试验在首次中期分析时因疗效显著而提前终止,bCBT组疲乏评分显著低于WLC组(后验概率99.94%,Cohen's d=1.12),且焦虑、健康相关生活质量及未来不确定性均改善。

要点

  • bCBT可显著降低弥漫性胶质瘤患者重度疲乏,效应量大(d=1.12)。
  • 干预后2周,bCBT组68%患者不再重度疲乏,WLC组为24%。
  • bCBT对焦虑、健康相关生活质量和未来不确定性也有改善作用。

核心结论

  • bCBT显著降低稳定期弥漫性胶质瘤患者的疲乏严重程度,并改善焦虑和健康相关生活质量。

研究设计与样本

  • 贝叶斯自适应随机对照试验,纳入47例稳定期弥漫性胶质瘤伴重度疲乏(CIS-fatigue≥35)患者,随机接受12周bCBT或等待名单对照(WLC)。

主要发现

  • bCBT组CIS-fatigue评分低于WLC组的后验概率为99.94%,标准化效应量Cohen's d=1.12(95%CI:0.43-1.81)。
  • 干预后2周,bCBT组68%患者不再重度疲乏,WLC组为24%。
  • 12周随访时bCBT组疲乏仍显著低于WLC组(d=1.22)。
  • bCBT对焦虑、健康相关生活质量和未来不确定性均有改善效应(d=0.42-1.19)。

临床怎么用

  • 对于稳定期弥漫性胶质瘤伴重度疲乏的患者,可考虑提供12周bCBT作为循证支持治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While severe fatigue is common in patients with diffuse glioma, no evidence-based treatment is currently available. The objective of this RCT was to evaluate the efficacy of blended cognitive behavioral therapy (bCBT) for severe fatigue. METHODS: Severely fatigued patients (Checklist Individual Strength, fatigue-severity subscale [CIS-fatigue] ≥ 35) with diffuse glioma and stable disease were randomized to 12 weeks of bCBT or a waiting list condition (WLC). The primary endpoint was fatigue severity 2 weeks after intervention. This Bayesian adaptive trial included prespecified interim analyses for efficacy at n = 40, 50, 60, 70, and 80. Secondary outcomes-health-related quality of life (HRQoL), anxiety, future uncertainty, and depression-were assessed at 2 and 12 weeks after intervention. RESULTS: The trial was stopped for efficacy at the first interim analysis. Of 47 patients randomized, 40 patients reached the primary endpoint (mean age 53 years, 47% female). The posterior probability that CIS-fatigue scores were lower with bCBT than with WLC was 99.94%, with a large standardized effect size (Cohen's d) of 1.12 [95% CI: 0.43-1.81]. At 2 weeks after intervention, 68% of patients were no longer severely fatigued after bCBT, compared to 24% in WLC. At 12 weeks follow-up, fatigue was still significantly lower in the bCBT group compared to WLC (d = 1.22). bCBT also demonstrated beneficial effects (d = 0.42-1.19) on anxiety, HRQoL, and future uncertainty. CONCLUSIONS: bCBT significantly reduces fatigue and improves anxiety and HRQoL in patients with diffuse glioma. These findings enable evidence-based supportive care strategies for reducing fatigue and enhancing HRQoL in this population.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Gorter M, Röttgering JG, Belgers V, et al. Bayesian adaptive randomized trial of blended cognitive behavioral therapy for severe fatigue in stable diffuse glioma. Neuro Oncol. 2026. PMID: 41208030. doi:10.1093/neuonc/noaf256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。